# TIGIT

Source: https://onco.cc/targets/tigit/  
OnCo record `tigit` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TIGIT is an inhibitory receptor on T and natural killer cells that binds PVR (CD155) on tumour cells, so blocking it was expected to amplify PD-1 and PD-L1 inhibitors. Tiragolumab, domvanalimab and others then failed to add benefit in phase 3 lung cancer trials despite encouraging phase 2 signals, and the lack of a TIGIT-specific biomarker remains a weakness.

## Summary

TIGIT is an inhibitory receptor on T and NK cells that binds PVR (CD155) on tumour cells and competes with the activating receptor CD226, so blocking it was expected to amplify PD-1 and PD-L1 inhibitors. That expectation largely failed in phase 3: tiragolumab (SKYSCRAPER-01), domvanalimab and others did not add meaningful benefit to PD-1/PD-L1 blockade in NSCLC or SCLC, despite encouraging phase 2 signals. Because TIGIT sits on immune cells, patient selection relied on PD-L1 rather than a TIGIT-specific biomarker, and this remains a weakness. Fc-enabled versus Fc-silent antibody design, which changes whether regulatory T cells are depleted, is still debated, and some programmes continue. The newcomer's lesson: TIGIT is a cautionary tale about promising early data that did not survive large randomised trials.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: checkpoint; failed-so-far
- Symbol: TIGIT
- Class: checkpoint
- Biology: Binds PVR (CD155) on tumour cells; competes with the activating receptor CD226.
- Where found: T and NK cells

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/TIGIT
- Wikipedia: https://en.wikipedia.org/wiki/TIGIT

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/)
- drugs: [HB0036](https://onco.cc/drugs/hb0036/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- pathways: [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [T-cell exhaustion](https://onco.cc/pathways/t-cell-exhaustion/)
- companies: [Compugen](https://onco.cc/companies/compugen/)
- pairings: [Caution: TIGIT + PD-(L)1 blockade](https://onco.cc/pairings/tigit-plus-pd1-caution/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/)
- targets: [CD112 (nectin-2)](https://onco.cc/targets/nectin2/), [CD155 (PVR)](https://onco.cc/targets/pvr/), [CD96](https://onco.cc/targets/cd96/), [PVRIG (CD112R)](https://onco.cc/targets/pvrig/), [TIM-3](https://onco.cc/targets/tim3/)
- terms: [Checkpoint (two meanings)](https://onco.cc/terms/checkpoint/), [Immune checkpoint](https://onco.cc/terms/immune-checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/tigit.json